Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and...

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Pain Management

Background:

• Cannabinoid derivative CB13 shows therapeutic potential for chronic pain.
• CB13 possesses unfavorable physicochemical properties hindering oral drug delivery.
• Current oral treatments for specific chronic pain states are limited.

Purpose of the Study:

• To develop and optimize lipid nanoparticles (LNP) for oral delivery of CB13.
• To enhance the physicochemical properties and stability of CB13 for therapeutic use.
• To evaluate the performance of LNP-CB13 formulations for potential chronic pain management.

Main Methods:

• CB13-loaded lipid nanoparticles (LNP) were prepared using solvent-emulsion evaporation.
• Formulations were optimized for physicochemical properties, long-term stability, and gastric integrity.
• In vitro interactions with NIH 3T3, HEK 293T, and Caco-2 cells were assessed.

Main Results:

• An optimized LNP formulation for CB13 was successfully developed.
• Lipid core selection, production parameters, and lecithin inclusion were critical factors.
• The optimized LNP formulation demonstrated good encapsulation, integrity, and stability.

Conclusions:

• Lipid nanoparticles represent a promising carrier for oral CB13 delivery.
• This LNP formulation could provide a viable oral treatment option for chronic pain.
• Further development may lead to effective pain management strategies using CB13.